BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 8
• 9
• 10
• 11
• 12
• 13
• 15
• 16
• 17
• 18
• 19
• 22
• 23
• 24
• 25
• 26
• 29
• 30
• 31

• 

  Deals

  Amylyx Rebuilds Momentum Following Relyvrio Market Withdrawal

  While supportive of Amylyx’s acquisition of a GLP-1 drug, analysts say the company’s future hinges on key upcoming readouts from multiple products in its pipeline.

  July 24, 2024

   · 

  5 min read

   · 

  Heather McKenzie
• 

  Adcomms

  FDA Flags Potential ‘Overtreatment’ for NSCLC With AstraZeneca’s Imfinzi Ahead of Adcomm

  AstraZeneca is proposing to use Imfinzi for resectable non-small cell lung cancer in the perioperative setting—both before and after surgical resection of the tumor. However, ahead of Thursday’s advisory committee meeting, FDA staffers have expressed concerns.

  July 24, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Deals

  Should Merck Buy Out Moderna on Keytruda–Cancer Vaccine Partnership?

  A longtime biopharma exec and Moderna shareholder argues in an anonymous email to the companies’ CFOs that they have a fiduciary responsibility to close the deal. Analysts say the proposal is interesting but “too simplistic.”

  July 24, 2024

   · 

  9 min read

   · 

  Jef Akst
• 

  Clinical research

  Biogen, Sage Scrap Essential Tremor Study After Phase II Failure

  Biogen and Sage Therapeutics’ investigational neuroactive steroid did not significantly improve upper limb tremors in patients with essential tremor, the companies announced Wednesday.

  July 24, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Job Trends

  Report: 2024 Job Market Trends, H2 Update

  This report investigates anticipated job search activity and hiring outlook for the remainder of 2024.

  July 24, 2024

   · 

  1 min read

   · 

  BioSpace Insights
• 

  Podcast

  Layoffs Persist, GLP-1s Launch for Weight Loss in China

  Despite early 2024 optimism, BioSpace’s Job Market Trends report outlines a still sluggish situation in the biopharma industry, Novartis and J&J announce Q2 earnings, GLP-1 market leaders expand into China and the Cassava Sciences saga continues.

  July 24, 2024

   · 

  1 min read

   · 

  Heather McKenzie
• 

  Series A

  J&J Alums Raise $165M Series A for Startup to Develop Biologics for Cancer, Autoimmune Diseases

  Third Arc Bio, led by three former Johnson & Johnson executives, is advancing a portfolio of multifunctional antibodies for cancer and inflammatory and immune-mediated diseases.

  July 24, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Pharmacy benefit managers

  PBM Execs Point Fingers at Pharma Industry in House Hearing on Rising Drug Prices

  Executives from the three largest pharmacy benefit manager companies testified Tuesday before Congress that rising drug prices in the U.S. are due to pharma companies taking advantage of market exclusivities and excessive charges.

  July 24, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Pfizer’s Hemophilia A Gene Therapy Candidate Gets Phase III Win

  The company’s candidate, giroctocogene fitelparvovec, met its primary and key secondary objectives of superiority compared to the standard treatment of regular Factor VIII infusions.

  July 24, 2024

   · 

  2 min read

   · 

  Kate Goodwin
• Press Releases

  Versiti, Inc. Names Matthew Anderson, MD, PhD, Executive VP and Chief Medical Officer

  July 24, 2024

   · 

  2 min read